Genetic determinants of left ventricular mass: The role of Beta-1 adrenoceptor variation in normal, athletic, and diseae populations  by Stanton, Tony et al.
JACC March 19.2003 ABSTRACTS - Vascular Disease, Hypertension, and Prevention 273A 
healthy study partlclpants were analyzed by whole-blood aggregometry. Platelet aggre- 
gation was determined by the increase in impedance across paired electrodes in 
response to the aggregatory agents collagen and ADP, respectively. For CV patients, 
these data were regarded for medication. Blood samples from healthy study participants 
were studied after addition of ACE inhibitors in different dosage titrations. Results: As 
the central flnding, platelet aggregation was attenuated ex viva by captopril and ramipril 
as well as by ASA and clopidogrel. While decrease in collagen-induced platelet aggrega- 
tion was significant with captopril (24%: P=O.O2) and ramipril (29%; P=O.O3), an adverse 
increase was seen with enalapril (11%; PcO.05). Following collagen induction, platelet 
aggregation decreased by 23% (PcO.01) with ASA and with ASAiclopidogrel by 35% 
(P=O.O4). After ADP induction, inhibition with ASA!clopidogrel was 85% (PcO.Ol), with 
ASA 19% (P=O.O3) and with captoprll there was a trend of inhibition (27%; P=O.l4); no 
significant antithrombotic effect was seen with ramiprrl or enalapril. In vitro, there was no 
significant change of platelet aggregation after addition of specific ACE Inhibitors. Con- 
clusions: Our findlngs provide direct evidence for ACE inhibitors to decrease platelet 
aggregation ex viva A differential anti-aggregatory profile of ACE inhibitors may explain 
different effects on CV events as observed in large clinical trials. Failure of effects in vitro 
suggests that the antithrombotic effect is not due to direct interaction between ACE inhib- 
itors and thrombocytes. 
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1132-120 Fish Oil Attenuates Ox-Low-Density Lipoprotein 
Induced Expression of Adhesion Molecules in Human 
Coronary Artery Endothelial Cells 
Honaiianq Chen, Dayuan Li. Tom Saldeen, Jawahar L. Mehta, University of Arkansas for 
Medical Sciences, Llttle Rock, AR. Central Arkansas Veterans Healthcare System, Little 
Rock, AR 
Background: A number of studies have suggested antt-atherosclerotic effects of fish/ 
fish oil. Uptake of oxidized low-density lipoprotein (ox-LDL) by endothelial cells is an 
early step in atherogenesis. Ox-LDL upregulates expression of adhesion molecules. 
such as P-selectin and intracellular adhesion molecule-l (ICAM-1). We hypothesized 
that fish oil components may reduce ox-LDL-mediated expression of adhesion mole- 
cules. 
Materials & Methods: Cultured human coronary artery endothelial cells (fourth ganera- 
tion) were incubated with ox-LDL (40&ml) for 24 hrs. Parallel groups of cells were pre- 
treated with docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) (IO and 50 
PM), the tw major components of fish oil, for overnight before incubation with ox-LDL. 
Another group of cells was treated with the protein kinase B (PKB) inhibitor wortmannin 
(100 nM) along with DHA (50 pM). 
Results: Ox-LDL markedly increased the expression of P-selectin and ICAM-I (both pro- 
tern and mRNA) in HCAECs, enhanced the adherence of monocytes to the cultured 
endothelail cells, and inhlbited the activity of PKB. Both EPA and DHA decreased ox- 
LDL-induced upregulation of P-se&tin and ICAM-I expression and adherence of mono- 
cytes, and increased the activity of PKB (all PqO.02 vs. ox-LDL alone, n=6). The effects 
of 50 pfv’ concentration were rnwe pronounced than the effects of IO @l (P<O.O5). 
Import&tly, the PKB inhibitor wortmann~n attenuated the effects of DHA (PcO.05). 
Conclusions: The present study shows that both EPA and DHA attenuate the ox-LDL- 
induced expression of adhesion molecules and the adherence of monocytes to the 
endothelial cells These effect of EPA and DHA are mediated by modulation of PKB 
activity. These effects of EPA’DHA may underlie the anti-atherosclerotic effects of fish/ 
fish oils. 
1132-121 Angiotensin Receptor Type 1 (AT,) Independent Growth 
Effects of Intracellular Angiotensin II (Ang II) in Cardiac 
Myocytes 
Ralesh Kumar, Sandhya Sanghi, Kenneth M. Baker, David E. Dostal, The Texas A & M 
University System Health Science Center, Temple, TX 
Background: Cardiac remodeling and growth can be elicited through autocrine and 
paracrine actions of Ang II, vra binding to the AT, plasma membrane receptor. An intrac- 
rim? role for Ang II has been postulated; however, no direct growth related evidence sup- 
ports this postulate. We present evidence of growth promoting effects of intracellular Ang 
II I” rat neonatal cardiac myocytes. Others and we have previously demonstrated AT, 
lkke intracellular Ang II bindlng sites on hepatocyte nuclear envelopes. 
Methods: Neonatal rat ventricular myocytes were infected with the Tet-off adenovirus 
coding for Ang II peptide (Ad_Ang II). The effect on growth was studied by sH-Leucine 
incorporation after 72 h of infection in the presence and absence of the cell permeable 
and impermeable Ang II receptor antagonists, losartan and candesartan, respectively. 
Intracellular and extracellular Ang II levels were measured by a competitive ELISA 
assay. 
Results: In myocytes infected with Ad_Ang II (72 h), the levels of intracellular Ang II 
were increased by 72.4 % (99 + 6 vs 58 * 15 PM) compared to control virus (Ad-Cow) 
An increase of 132 % (378 r 70 vs 162 * 39 PM) in extracellular Ang II levels was also 
observed, possibly due to a positlve-feedback loop. In Ad_Ang II treated myocytes, there 
was a 63.7 f 39.6 % increase in 3H-Leucine incorporation, which was not blocked by 
losartan and candesartan, indicating that this effect was mediated through mechanisms 
independent of an AT, like plasma membrane or nuclear receptor. Conditidned medium 
obtained from Ang II expressing cells stimulated growth in naive cells by 11.1 + 3.5 %. 
which was completely blocked by losartan and candesartan. 
Conclusion: Intracellular Ang II promotes cardiac myocyte growth through mechanisms 
independent of plasma membrane AT, receptor activation and secreted growth factors. 
This observation may represent a second level of control for Ang II mediated growth and 
provides a potentially important target for therapeutic inten ention. 
1132-122 Genetic Determinants of Left Ventricular Mass: The 
Role of Beta-l Adrenoceptor Variation in Normal, 
Athletic, and Disease Populations 
TOW Stanton, John R. Payne, Hugh E. Montgomery, Graham Watt, Anna F. Dominlczak. 
Alan G. Jardine, John M. Connell, University of Glasgow, Glasgow, United Kingdom, 
Unwersity College London, London, United Kingdom 
Background: Left ventricular (LV) mass is an extremely strong predrctor of cardiovascu- 
lar morbidity and mortality in the general population. The beta-l adrenoceptor (Bl AR) is 
a key cell surface signalling protein expressed in the heart. As beta-blocker therapy is 
cardloprotective and myocyie growth is stimulated by receptor agonists. it is possible that 
variation in the receptor gene may affect LV mass.The gene of the Bl AR has two known 
functlonal polymorphisms; one of these confers an amino acid change at position 389 
from glycine (G) to arginine (C). The arginlne-form of the receptor (C) has been demon- 
strated to have far greater actlvrty when bound by agonist and also increased GTP bind- 
ing. Methods & Results: We therefore examined the relationship between this variation 
in the BlAR gene and the effect on LV mass in 3 different populations.The first com- 
prised 2280 healthy individuals with ECG-derived LV mass. No significant difference was 
found between LV mass and BIAR genotype. The second population comprised 207 
healthy males who underwent a IO week cardiovascular training programme. LV mass 
was determined by MRI at the start and end of the training period. No difference was 
found for the increase in LV mass when analysed for BIAR genotype. The third popula- 
bon comprised 249 patients with renal disease with echocardiographically determined LV 
mass. There was a highly significant difference in LV mass between the GG group when 
compared to the other 2 groups, CG:GG pqO.05 and CC:GG pcO.01. There were no sig- 
nificant difference in blood pressure measurments, ejection fraction or age between gen- 
otypes.Omining those on renal replacement therapy, beta-blockers or ACE inhibitors did 
not diminish the strength of the association. 
Conclusion: GenetIc variation at the Bl AR locus is of greater importance in defining LV 
mass in pathologkxl circumstances. 
1132-123 Effects of Vascular Endothelial Growth Factor on 
Proliferation and Differentiation of Embryonic Stem 
Cells 
Yu Chen Yinke Yang, Qingen Ke, Jamal S. Rana, James P. Morgan, Yang-Fu Xrao, -3 
Harvard Medical School, Boston, MA 
Our previous study showed that compared to transplantation of embryonic stern cells 
(ESCs) alone in infarcted hearts, improvement of cardiac function was significantly 
greater in post-infarcted mice transplanted with ESCs overexpressing vascular endothe- 
lial growth factor (VEGF). Accumulated evidence demonstrates that VEGF affects 
embryonic development and stimulates vascular growth. In the present study, we investi- 
gated the effects of VEGF, in vitro, on ESC proliferation and differentiation in the pres- 
ence or absence of leukemia inhibitory factor (LIF). ESC proliferation was measured by 
the MTr method (Cell proliferation kit I, sigma). Compared to the control group, 20 ng/ml 
VEGF did not affect proliferation of ESCs cultured in the presence of LIF (1000 units/ml) 
at 6 and 11 days. However, in the absence of LIF, 20 ngiml VEGF significantly enhanced 
ESC proliferation. The numbers of cells were significantly increased by 45 -t 5% (n = 7) 
and by 79 * 7% (n = 7) at 6 and 11 days in culture, respectively. Similar results were 
observed in the expenments of ESCs transfected with VEGF cDNA (phVEGF165). In 
addition, the hanging drops method was used to evaluate differentiation of ESCs cultured 
in the absence of LIF. The portion of ESCs that differentiated to cardiac a-myow heavy 
chain @-MHC) positive cells was sorted by flow cytometry. Compared to VEGF- 
untreated ESCs. 20 @ml VEGF increased the number of a-MHC positive cells by 84 f 
8% (n = 3) at 11 days in culture. In ESCs transfected with VEGF cDNA. the number of a- 
MHC posltwe cells was increased by 52 * 7% (n = 3) at 11 days in culture Moreover, 
WeStern blot analysis further confirmed that in the absence of LIF, the amwnt ofa-MHC 
protein was significantly increased in ESCs treated with 20 ngiml VEGF or in ESCs 
transfected with VEGF-cDNA. Our data demonstrate that VEGF did not affect orollfera- 
tlon of ESCs cultured in the presence of LIF, but stimulated proliferation and dlfferentia- 
tion of ESCs cultured in the absence of LIF. The information of the VEGF-Induced 
significant increase in differentiation of ESCs to cardiac a-MHC positive cells is probably 
important for future cell therapy to regenerate injured myocardium. 
1132-124 Location of Mutation in the KCNQI Gene Does Not 
Influence Outcome of Long QT Syndrome Patients 
Woiciech Zareba, Arthur J. Moss, Gloria Sheu, Elizabeth S. Kaufman, Jennifer L 
Robinson, Mark L. Andrew, Elizabeth Carroll, for International LQTS Registry 
University of Rochester, Rochester, NY 
Background. Recent data showed that long QT syncrome (LQTS) patrents with mu:ations 
in the pore region of HERG (LQT2) gene have significantly higher risk of cardiac events 
than patients with mutations in non-pore region. The aim of this study was to determine 
whether there IS an association between location of mutations in the KCNQI gene and 
cardiac events in LQTI patients. 
Methods. Study population consisted of 216 LQTI patients with KCNQI gene mutation. 
Demographic, clinical. and follow-up informabon was compared among patients with dif- 
ferent location of KCNQI mutations defined as: prs-pore region including N-terminus (I- 
